Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.

Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Preziosa P, Ravnborg M, Rieckmann P, Rocca MA, Wynn D, Young C, Filippi M.

Mult Scler. 2013 Jul;19(8):1074-83. doi: 10.1177/1352458512469695. Epub 2012 Dec 12.

PMID:
23234810
2.

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group.

Lancet. 2009 Oct 31;374(9700):1503-11. doi: 10.1016/S0140-6736(09)61259-9. Epub 2009 Oct 6. Erratum in: Lancet. 2010 Apr 24;375(9724):1436.

PMID:
19815268
4.

Early treatment: PreCISe-ly what the patient needs.

Montalban X.

J Neurol Sci. 2009 Dec;287 Suppl 1:S2-6. doi: 10.1016/S0022-510X(09)71293-6.

PMID:
20106344
5.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Clerico M, Faggiano F, Palace J, Rice G, Tintorè M, Durelli L.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005278. doi: 10.1002/14651858.CD005278.pub3. Review.

PMID:
18425915
6.

Ten-year follow-up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial.

Simon JH, Kinkel RP, Kollman C, O'Connor P, Fisher E, You X, Hyde R; CHAMPIONS Investigators Group.

Mult Scler. 2015 Apr;21(4):415-22. doi: 10.1177/1352458514547407. Epub 2014 Oct 24.

PMID:
25344370
7.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1087-97. Erratum in: N Engl J Med. 2012 Oct 25;367(17):1673.

8.

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.

Carter NJ, Keating GM.

Drugs. 2010 Aug 20;70(12):1545-77. doi: 10.2165/11204560-000000000-00000. Review.

PMID:
20687620
9.
10.

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.

Wolinsky JS, Narayana PA, Johnson KP; Multiple Sclerosis Study Group and the MRI Analysis Center.

Mult Scler. 2001 Feb;7(1):33-41.

PMID:
11321192
11.

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.

Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M; oral cladribine for early MS (ORACLE MS) Study Group.

Lancet Neurol. 2014 Mar;13(3):257-67. doi: 10.1016/S1474-4422(14)70005-5. Epub 2014 Feb 4.

PMID:
24502830
12.

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.

Filippi M, Wolinsky JS, Comi G; CORAL Study Group.

Lancet Neurol. 2006 Mar;5(3):213-20. Erratum in: Lancet Neurol. 2006 May;5(5):383.

PMID:
16488376
13.

[Long-term effects of glatiramer acetate in multiple sclerosis].

Brochet B.

Rev Neurol (Paris). 2008 Nov;164(11):917-26. doi: 10.1016/j.neurol.2008.02.045. Epub 2008 May 16. French.

PMID:
18790510
14.

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications.

Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M; European/Canadian Glatiramer Acetate Study Group.

Brain. 2001 Sep;124(Pt 9):1803-12.

PMID:
11522582
15.

Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.

Pakdaman H, Sahraian MA, Fallah A, Pakdaman R, Ghareghozli K, Ghafarpour M, Rahimian E, Shirani A.

Acta Neurol Scand. 2007 Jun;115(6):429-31.

PMID:
17511854
16.

[Brain MRI findings in Japanese patients with clinically isolated syndrome].

Tanaka M, Motoyama R, Tahara M, Tanaka K.

Rinsho Shinkeigaku. 2012;52(10):725-9. Japanese.

PMID:
23064621
17.

Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.

Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, Kolodny S, Zivadinov R.

Mult Scler. 2017 May;23(6):818-829. doi: 10.1177/1352458516664033. Epub 2016 Aug 8.

PMID:
27503905
18.

Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis.

Sombekke MH, Wattjes MP, Balk LJ, Nielsen JM, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F.

Neurology. 2013 Jan 1;80(1):69-75. doi: 10.1212/WNL.0b013e31827b1a67. Epub 2012 Dec 12.

PMID:
23243070
19.

Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.

Moraal B, Pohl C, Uitdehaag BM, Polman CH, Edan G, Freedman MS, Hartung HP, Kappos L, Miller DH, Montalban X, Lanius V, Sandbrink R, Barkhof F.

Arch Neurol. 2009 Nov;66(11):1345-52. doi: 10.1001/archneurol.2009.243.

PMID:
19901165
20.

Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis.

Swanton JK, Fernando KT, Dalton CM, Miszkiel KA, Altmann DR, Plant GT, Thompson AJ, Miller DH.

Mult Scler. 2010 Feb;16(2):156-65. doi: 10.1177/1352458509353650. Epub 2010 Jan 19.

PMID:
20086028

Supplemental Content

Support Center